Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis
- PMID: 22972862
- PMCID: PMC3518880
- DOI: 10.1093/cid/cis798
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis
Abstract
Background: Active tuberculosis is common among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, but the hazard of subsequent tuberculosis disease has not been quantified in a single prospective cohort.
Methods: Among HIV-infected, BCG-immunized adults with CD4 counts ≥200 cells/μL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania, we compared the prospective risk of active tuberculosis between subjects who did and who did not report prior active tuberculosis. All subjects with a positive tuberculin skin test without prior active tuberculosis were offered isoniazid preventive treatment. Definite or probable tuberculosis was diagnosed during active follow-up using rigorous published criteria.
Results: We diagnosed 52 cases of definite and 92 cases of definite/probable tuberculosis among 979 subjects during a median follow-up of 3.2 years. Among the 80 subjects who reported prior active tuberculosis, 11 (13.8%) subsequently developed definite tuberculosis and 17 (21.3%) developed definite/probable tuberculosis, compared with 41 (4.6%) and 75 (8.3%), respectively, of 899 subjects without prior active tuberculosis (definite tuberculosis risk ratio [RR], 3.01; 95% confidence interval [CI], 1.61-5.63, P < .001; definite/probable tuberculosis RR, 2.55; 95% CI, 1.59-4.09, P < .001). In a Cox regression model adjusting for age, CD4 count, and isoniazid receipt, subjects with prior active tuberculosis had substantially greater hazard of subsequent definite tuberculosis (hazard radio [HR], 3.69; 95% CI, 1.79-7.63, P < .001) and definite/probable tuberculosis (HR, 2.78; 95% CI, 1.58-4.87, P < .001).
Conclusions: Compared to subjects without prior tuberculosis, the hazard of active tuberculosis is increased 3-fold among HIV-infected adults with prior active tuberculosis. Clinical Trials Registration. NCT0052195.
Trial registration: ClinicalTrials.gov NCT00052195.
Similar articles
-
Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.BMC Infect Dis. 2019 Jan 17;19(1):62. doi: 10.1186/s12879-019-3696-x. BMC Infect Dis. 2019. PMID: 30654753 Free PMC article.
-
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.AIDS. 2010 Mar 13;24(5):675-85. doi: 10.1097/QAD.0b013e3283350f1b. AIDS. 2010. PMID: 20118767 Free PMC article. Clinical Trial.
-
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.J Infect Dis. 2010 Oct 15;202(8):1265-72. doi: 10.1086/656332. J Infect Dis. 2010. PMID: 20812851 Free PMC article. Clinical Trial.
-
New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection.Int J Tuberc Lung Dis. 2012 Jun;16(6):718-23. doi: 10.5588/ijtld.11.0444. Epub 2012 Apr 9. Int J Tuberc Lung Dis. 2012. PMID: 22507085 Review.
-
Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.Int J Tuberc Lung Dis. 1999 Aug;3(8):646-50. Int J Tuberc Lung Dis. 1999. PMID: 10460096 Review.
Cited by
-
Predictors and short-term outcomes of recurrent pulmonary tuberculosis, Uganda: a cohort study.S Afr Respir J. 2017;23(4):106-112. S Afr Respir J. 2017. PMID: 29368752 Free PMC article.
-
Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3(Suppl 3):S297-305. doi: 10.1097/QAI.0000000000000497. J Acquir Immune Defic Syndr. 2015. PMID: 25768869 Free PMC article. Review.
-
Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs.Int J Tuberc Lung Dis. 2017 Mar 1;21(3):256-262. doi: 10.5588/ijtld.16.0478. Int J Tuberc Lung Dis. 2017. PMID: 28225335 Free PMC article.
-
Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines.Pharm Res. 2018 Nov 8;36(1):8. doi: 10.1007/s11095-018-2528-9. Pharm Res. 2018. PMID: 30411187 Free PMC article. Review.
-
Loss to follow-up among people living with HIV on tuberculosis preventive treatment at four regional referral hospitals, Uganda, 2019-2021.J Clin Tuberc Other Mycobact Dis. 2024 Jun 8;36:100454. doi: 10.1016/j.jctube.2024.100454. eCollection 2024 Aug. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 38966799 Free PMC article.
References
-
- Heimbeck J. The infection of tuberculosis. Acta Medica Scandinavica. 1930;74:143–55.
-
- Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Resp Crit Care Med. 2005;171:1430–5. - PubMed
-
- Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345–9. - PubMed
-
- Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med. 1993;119:194–8. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials